Wow!
It matters not to PER
Why?
1) Boys that can access the gene therapy drug will get it
others will use other therapies..
2)The cost $3.2 million will be a stumbling block
3) US clinicians are skeptical re efficacy
4)Sarepta is yet to make a profit from the other exon skipping drug
5)Gene therapy has still got a long way to go before it’s widely accepted
6) All in all PER will continue with its path forward
Other exon skipping drugs will use combination therapies.. eg Atl1102
.
https://finance.yahoo.com/news/sarepta-therapeutics-announces-expanded-us-210200030.html
- Forums
- ASX - By Stock
- PER
- FDA approves Sareptas Srp901 for the whole population
FDA approves Sareptas Srp901 for the whole population
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.0¢ | 8.2¢ | 8.0¢ | $20.85K | 257.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 89846 | 7.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 27441 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 89846 | 0.079 |
3 | 251119 | 0.078 |
2 | 207500 | 0.077 |
3 | 84700 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 27441 | 1 |
0.082 | 66358 | 2 |
0.083 | 238277 | 2 |
0.084 | 157142 | 2 |
0.085 | 553000 | 3 |
Last trade - 11.24am 17/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |